Baicalin, a flavonoid derived from the roots of Scutellaria baicalensis (Chinese skullcap), has been investigated for its potential to support or treat ulcers, particularly gastric ulcers. Scientific studies, primarily in vitro and in animal models, have demonstrated several mechanisms by which baicalin may exert protective effects on the gastric mucosa. These include its anti-inflammatory action—by inhibiting pro-inflammatory cytokines such as TNF-α and IL-6—its antioxidant properties, and its ability to enhance mucosal defense through upregulation of protective factors like prostaglandin E2. Some studies also suggest baicalin may inhibit Helicobacter pylori, a bacterium implicated in ulcer formation, though direct clinical trials in humans are sparse.

While there is a long tradition of using Scutellaria baicalensis in traditional Chinese medicine for gastrointestinal complaints, the use of isolated baicalin for ulcer management is supported by preclinical (animal and cell-based) research rather than robust human clinical data. No large-scale, high-quality randomized controlled trials have been published to firmly establish its efficacy in humans with ulcers. Therefore, while there is promising scientific evidence from laboratory and animal research, the overall quality and quantity of evidence is moderate, warranting further investigation before strong clinical recommendations can be made.